Today - CytomX announced the acquisition of drug conjugate linker-toxin and CD3-based bispecific technologies from Agensys, Inc.
This announcement increases the probability that probody drug conjugate technology is working in the clinic. The second part of our 1H parlay is the results from CX-2009 targeting CD166.
In addition, Eli Lilly agreed to buy Loxo Oncology today for about $8B. Aquilo Capital Management, who is a large investor in CTMX had Loxo as its second largest position as of 9/30/2018.